Fig. 1From: Large variation in anti-factor Xa levels with nadroparin as thromboprophylaxis in COVID-19 and non-COVID-19 critically ill patientsWeight versus anti-FXa levels with three thromboprophylactic dosages of nadroparinBack to article page